September 24, 2019 Clinical Research/Diagn.

GE Healthcare expands oncology PET tracer portfolio – aims to improve patient response rates to immunotherapies

Partnering with multiple companies to develop targeted PET imaging tracers to better predict and monitor individual patient response to immunotherapies PET tracers would help increase patient response rates which currently average between 20-40% Initially PET tracers would support pharma companies to enhance clinical trials enabling speed-to-market for immunotherapies Chalfont St Giles, UK –September 24 2019... Read more

September 23, 2019 Clinical Research/Diagn. PR/Corporate

Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress

Basel, 23 September 2019 Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medicine’s FoundationOne® Liquid biopsy assay... Read more

September 18, 2019 Clinical Research/Diagn. M&A, Partnerships

BD partners with global organizations to support diagnostic testing for AMR

Sep 18, 2019 For the third time in five years, Fortune has named BD to its list of companies that are Changing the World , this year recognizing the company for its significant global efforts and investments to combat antimicrobial resistance (AMR) in the areas of infection prevention, diagnostics, surveillance and reporting. Through its decades of experience in collaborating to... Read more

September 11, 2019 Clinical Research/Diagn. M&A, Partnerships

FOSS and Technical University of Denmark enter partnership

HILLERØD, 11. September, 2019. FOSS and DTU, Technical University of Denmark, join forces around common interests within research, development and education. A new strategic partnership between DTU and FOSS will strengthen the existing relations within research, development and education. The aim is to create a platform for common projects and goals, and to ensure a... Read more

September 10, 2019 Clinical Research/Diagn. Licensing, IP, and Legal Mass Spectrometry

Fluidigm Files Patent Infringement Suit Against IONpath

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court for the Northern District of Californiaseeking to stop the infringement of its patented technology by IONpath. In... Read more

September 10, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Announces Collaboration to Develop Advanced Analytical Workflows for Clinical Laboratories

San Jose, Calif. – (September 3, 2019) – Thermo Fisher Scientific, the world leader in serving science, and Cedars-Sinai, a leading nonprofit academic healthcare organization, have entered into a collaboration to develop a pathway to precision medicine through the development of robust, reliable and sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows for clinical research applications. Bringing together... Read more

September 9, 2019 Clinical Research/Diagn. M&A, Partnerships PR/Corporate

Ground-breaking trial demonstrates potential of blood test which harnesses the power of the immune system to reduce late detection of lung cancer

9 September 2019, Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, welcomes the presentation of data today by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT® Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.... Read more

September 9, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor

Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered non-small cell lung cancer and thyroid cancer patients who may be suitable for LOXO-292, Lilly’s RET inhibitor CARLSBAD, Calif., Sept. 9, 2019 /PRNewswire/ — Thermo... Read more

September 6, 2019 Clinical Research/Diagn. Product Launch

European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

Basel, 06 September 2019 European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC) Decision based on data showing that the Tecentriq plus... Read more

September 5, 2019 Clinical Research/Diagn.

New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy

New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy CARLSBAD, Calif., Sept. 5, 2019 /PRNewswire/ — Tumor mutational burden (TMB) has recently emerged as a potential biomarker to help guide ICI (immune checkpoint inhibitor) therapy. A new study published in The Journal of Pathology further establishes TMB’s... Read more